Macquarie analyst Tao Qiu lowered the firm’s price target on Surgery Partners (SGRY) to $34 from $35 and keeps an Outperform rating on the shares. The firm notes the company reported an in-line quarter and reaffirmed revenue/adjusted EBITDA guidance. Free cash flow outlook tempered due to elevated transaction spending and others, Macquarie says, adding that case volume led organic revenue growth, while rate was affected by mix shift but remains strong year-to-date.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGRY:
- Surgery Partners Reports Q3 Revenue Growth Amid Challenges
- Surgery Partners reports Q3 adjusted EPS 19c, consensus 25c
- Surgery Partners sees FY24 revenue greater than $3.075B, consensus $3.09B
- SGRY Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- 3 Best Stocks to Buy Now, 10/14/2024, According to Top Analysts
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
